ITRM
Iterum Therapeutics plc
Iterum Therapeutics plc (ITRM) is currently in a downtrend, trading below both the 50-day and 200-day moving averages. RSI is at 33.7, with 0/3 trend checks passing.
ITRM with MA50 and MA200
Key levels & signals
Iterum Therapeutics plc (ITRM) currently looks weaker on the chart and is not showing much trend strength. The latest available price is $0.03, and 0 of 3 core trend checks are currently passing. Price is trading below the 50-day moving average by 85.1% and below the 200-day moving average by 96.0%.
ITRM currently has an RSI reading of 33.7, which leans a little softer than neutral. That does not automatically make the chart bearish, but it does suggest momentum is not especially strong right now.
For traders reviewing ITRM next, the main question is whether weakness is starting to stabilise or whether the chart still looks vulnerable to further downside. Some traders may watch for bounce attempts, but others will want to see stronger proof that the trend is improving before treating the stock as a cleaner setup.
About Iterum Therapeutics plc
Iterum Therapeutics plc is a clinical-stage biopharmaceutical firm dedicated to the development and commercialization of anti-infective treatments. The company operates across Ireland, Bermuda, and the United States. Its primary therapeutic candidate is sulopenem, an innovative antimicrobial compound available in both oral and intravenous formulations. Sulopenem is currently undergoing advanced (Phase III) clinical evaluation for its potential in addressing uncomplicated and complicated urinary tract infections, as well as complicated intra-abdominal infections. Established in 2015, Iterum Therapeutics maintains its corporate headquarters in Dublin, Ireland.
Learn the indicators behind this page
More stock opportunities
Common questions about ITRM
Is this page a buy or sell recommendation?
No. This page is designed to help you review chart structure, momentum and technical context more quickly, but it is not personal financial advice.
Why can a stock look bullish and overbought at the same time?
Strong trending stocks can still become stretched in the short term. That is why trend traders and dip buyers can read the same chart differently.
What should I do next after reading this page?
Open the full dashboard, review the chart in more detail, compare indicators, and decide whether the setup still makes sense within your own process.